Navigation Links
IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Date:9/12/2012

MENLO PARK, Calif., Sept. 12, 2012 /PRNewswire/ -- IncellDx, Inc. announced today that it has initiated a large-scale study called SLIQUE (study to compare slideless and liquid-based Pap smears). The study is being conducted in partnership with BioReference Laboratories, Inc. (NASDAQ: BRLI) and is expected to take anywhere from three to six months.  Over 10,000 samples will be used to compare the performance of OncoTect 3Dx™ technology with liquid-based cytology (ThinPrep™ and SurePath™) methods. IncellDx recently presented on OncoTect 3Dx™ at the Eurogin Conference (http://www.eurogin.com/2012) and this study represents the next step in commercializing the technology.

Current Pap smear technology is slide-based and requires manual review of each slide by specially trained technicians, increasing cost and reducing throughput. OncoTect 3Dx™ uses a proprietary flow cytometry-based technology to improve and automate the process. "Liquid-based cytology represents an approximately $5 billion market opportunity for IncellDx," said Bruce Patterson, MD, CEO and Founder of IncellDx. "Our OncoTect 3Dx™ technology has the potential to increase the sensitivity and specificity of the liquid-based Pap smear while it simultaneously reduces the cost and turnaround time."

"This is a very interesting technology that opens up new horizons as we continue to innovate in the women's health space," said Marc Grodman, MD, CEO of BioReference Laboratories and Chairman of the Board of IncellDx. "We expect that OncoTect 3Dx™ has the potential to be disruptive in the marketplace both here in the United States and anywhere in the world where cytology resources are scarce."

IncellDx and BioReference expect the study to provide sufficient data to plan a FDA trial for the OncoTect 3Dx™ technology.

More information about OncoTect® and OncoTect 3Dx™:

About IncellDx, Inc.  
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.

ThinPrep™ is a trademark owned by Hologic and SurePath™ is a trademark owned by BD.


'/>"/>
SOURCE IncellDx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):